Is a complete AVTX research report available?

No complete published report is available for Avalo Therapeutics, Inc. (AVTX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Avalo Therapeutics, Inc. (AVTX)

NASDAQ: AVTX · USD

$19.4

+0.38 (+2.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AVTX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	1B
Revenue (ttm)	59K
Net income (ttm)	-84.7M
EPS (ttm)	-$5.36
Shares out	52.9M
Volume	935,219
Beta	0.79
Price target	$44.7	+130.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 59K
Net income (ttm): -84.7M
EPS (ttm): -$5.36
Market cap: 1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AVTX indicators

Market & fundamental data

Available fields

200

Groups with data

Currency

USD

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001534120
Company name	Avalo Therapeutics, Inc.
Country	United States
Country code	US
Cusip	05338F306
Employees	33
Employees Change	10%
Employees Change Percent	43.48
Enterprise value	$944.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-10-15
Isin	US05338F3064
Last refreshed	2026-07-31
Market cap	$1B
Market cap category	Small-Cap
Price	$19.39
Price currency	USD
Rev Per Employee	1,787.88x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	AVTX
Website	https://www.avalotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.26%
EV/Sales	16,002.1x
FCF yield	-5.82%
P/B ratio	6.99x
P/S ratio	17,386.25x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-39.5M
Net Income	$-84.7M
Net Income Growth Years	0%
Pretax Margin	-143,340.68%
Profit Per Employee	$-2.6M
ROA	-41.5
Roa5y	-46.71
ROCE	-89.66
ROE	-88.76
ROIC	-51.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-46.94%
Cagr1y	196.7%
Cagr3y	-24.73%
Cagr5y	-69.83%
EPS Growth Quarters	1
EPS Growth Years	5
Revenue Growth	-86.62x
Revenue Growth Years	0x
Revenue Growth3 Y	-84.96x
Revenue Growth5 Y	-57.82x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0
Assets	$99.9M
Cash	$82M
Current Assets	$88.8M
Current Liabilities	$11.6M
Debt	$328,000
Debt Equity	$0
Equity	$68.3M
Liabilities	$31.6M
Long Term Assets	$11.1M
Long Term Liabilities	$20M
Net Cash	$81.7M
Net Cash By Market Cap	$7.96
Net Cash Growth	-34.27%
Net Debt Equity	$-1.2
Tangible Book Value	$57.8M
Tangible Book Value Per Share	$2.35
WACC	8.59

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.66
Net Working Capital	$-4.4M
Quick ratio	7.07
Working Capital	$77.2M
Working Capital Turnover	$0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-131.04%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.82%
1Y total return	196.48%
200-day SMA	16.5
3Y total return	-57.37%
50-day SMA	16.97
50-day SMA vs 200-day SMA	50over200
5Y total return	-99.75%
All Time High	22,031.5
All Time High Change	-99.91%
All Time High Date	2019-02-27
All Time Low	3.39
All Time Low Change	471.98%
All Time Low Date	2025-05-14
ATR	1.22
Beta	0.79
Beta1y	1.67
Beta2y	1.14
Ch YTD	6.77
High	19.88
High52	24.27
High52 Date	2026-05-07
High52ch	-20.11%
Low	18.98
Low52	6.51
Low52 Date	2025-07-30
Low52ch	197.85%
Ma50ch	14.27%
Premarket Change Percent	0.53
Premarket Price	$19.11
Price vs 200-day SMA	17.52%
RSI	56.42
RSI Monthly	34.06
RSI Weekly	57.99
Sharpe ratio	1.59x
Sortino ratio	3.02
Total Return	-131.04%
Tr YTD	6.77
Tr1m	0.52%
Tr1w	9.18%
Tr3m	46.89%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	15
Analyst Count Top	12
Analyst Price Target Top	$45.18
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.63
Operating Income	$-79.2M
Operating margin	-134,164.4
Price target	$44.69
Price Target Change	$130
Price Target Change Top	$133

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	40,650,440%
Float Percent	76.84%
Shares Insiders	1.5%
Shares Institutions	61.96%
Shares Out	52,902,989
Shares Qo Q	10.28%
Shares Yo Y	131.04%
Short Float	31.19%
Short Ratio	6.31
Short Shares	23.97

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-73.6M
Adjusted OCF	-73,647,000
Average Volume	1,010,113.25x
Bv Per Share	2.77
Ch10y	-99.82
Ch1m	0.52
Ch1w	9.18
Ch1y	196.5
Ch3m	46.89
Ch3y	-57.37
Ch5y	-99.75
Ch6m	27.15
Change	2%
Change From Open	1.95
Close	19.01
Days Gap	0.05
Depreciation Amortization	226,000
Dollar Volume	18,133,896.4
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-79.2M
EBITDA	$-78.9M
EPS	$-5.36
F Score	1
FCF	$-59.7M
FCF EV Yield	-6.32x
FCF Per Share	$-1.13
Financing CF	15,986,000
Fiscal Year End	December
Founded	2,011
Goodwill	10,502,000
Income Tax	$169,000
Investing CF	-56,215,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-13
Last Report Date	2026-03-31
Last Split Date	2023-12-29
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	16.27
Ma150ch	19.2%
Ma20	18.92
Ma20ch	2.5%
Net CF	-99,921,000
Next Earnings Date	2026-08-10
Open	19.02
Optionable	Yes
Position In Range	45.56
Ppne	375,000
Pre Close	19.01
Price Date	2026-07-30
Ptbv Ratio	17.74
Relative Volume	0.93x
Revenue	59,000x
SBC By Revenue	23,652.54x
Share Based Comp	13,955,000
Tax By Revenue	286.44x
Tr6m	27.15%
Us State	Pennsylvania
Volume	935,219
Z Score	-4.8

Avalo Therapeutics, Inc. (AVTX)

Coverage state: Market snapshot only — no published research

Generate the first AVTX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AVTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AVTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AVTX

Frequently asked questions